Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

US Patent 11167029 · Granted Nov 9, 2021

Estimated economic value: $12,286,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tandem diabody for CD16A-directed NK-cell engagement2025
Tandem diabody for CD16A-directed NK-cell engagement2025
Tandem diabody for CD16A-directed NK-cell engagement2025
Bispecific EGFR/CD16 antigen-binding protein2024
Bispecific EGFR/CD16 antigen-binding protein2024
Multivalent FV antibodies2023
Multivalent FV antibodies2023
Combination of an anti-CD16A antibody with a cytokine2022
Combination of an anti-CD16A antibody with a cytokine2022
Bispecific EGFR/CD16 antigen-binding protein2022
Bispecific EGFR/CD16 antigen-binding protein2022
Antibodies directed to HER-3 and uses thereof2022